Clinical Trial Update: An Efficacy, Pharmacokinetics, Safety and Tolerability Study of TMC435 as Part of a Treatment Regimen for Hepatitis C-Infected Patients [Phase 3]

View source ↗

Summary

Phase 3 study results for TMC435 in a hepatitis C treatment regimen, reporting efficacy, pharmacokinetics, safety and tolerability.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• TMC435

Snippet

Sponsor: Janssen R&D Ireland | Conditions: Hepatitis C, Chronic | Phase 3 | Status: COMPLETED | Results posted: 2015-08-13